World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
73
Citations
21284
World Ranking
2121
National Ranking
187

F. de Wolf publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where F. de Wolf sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 222 publications — 42nd percentile

42% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

F. de Wolf D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where F. de Wolf sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 73 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

F. de Wolf is affiliated with Imperial College London in the United Kingdom. Their research primarily focuses on the field of Medicine, with significant contributions to Infectious Diseases, Epidemiology, Internal Medicine, Oncology, and Emergency Medicine. Their work explores several interrelated topics within clinical research and infectious diseases.

The scientist has contributed to areas including:

  • COVID-19 Clinical Research Studies
  • Infectious Encephalopathies and Encephalitis
  • Sepsis Diagnosis and Treatment
  • Venous Thromboembolism Diagnosis and Management
  • COVID-19 and healthcare impacts
  • HIV/AIDS drug development and treatment
  • HIV/AIDS Research and Interventions

Their recent publications include the following:

  • COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients, 2021, PLoS ONE
  • Abstract 445: Natural history of coagulopathy in patients with cancer infected with COVID19: A real-world data (RWD) analysis, 2022, Cancer Research
  • Comparative Effectiveness of Initial Antiretroviral Therapy Regimens: ACTG 5095 and 5142 Clinical Trials Relative to ART-CC Cohort Study, 2020, UNC Libraries
  • Abstract 6655: A real world analysis: Impact of clinical trial eligibility criteria on clinical outcomes among patients with advanced non-small cell lung cancer (aNSCLC) receiving second line (2L) immune checkpoint inhibitor (ICI) therapy, 2023, Cancer Research

Frequently publishing in venues such as Cancer Research, PLoS ONE, and UNC Libraries, F. de Wolf has contributed primarily to journals with a focus on clinical oncology, infectious diseases, and broader medical research.

The scientist has collaborated with several fellow researchers, notably:

  • Monika A. Izano
  • Anette Schrag
  • Thomas D. Brown
  • Mark Stewart
  • Carla Rodriguez-Watson

F. de Wolf's scholarly activity touches on multiple aspects of infectious disease research, including the clinical aspects of COVID-19 and HIV/AIDS, with a notable link to real-world clinical data and treatment effectiveness. Their interdisciplinary approach connects epidemiology, internal medicine, and oncology to address pressing medical challenges.

Best Publications

  • Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.

    Jonathan A C Sterne;Margaret May;Dominique Costagliola;Frank de Wolf

  • Future challenges for clinical care of an ageing population infected with HIV: a modelling study

    Mikaela Smit;Kees Brinkman;Suzanne Geerlings;Colette Smit

  • Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.

    M. Tersmette;R. A. Gruters;F. De Wolf;R. E. Y. De Goede

  • Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality.

    M. Tersmette;J. M. Lange;R. E. de Goede;F. de Wolf

  • Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs.

    F Miedema;A J Petit;F G Terpstra;J K Schattenkerk

  • Late presentation of HIV infection: a consensus definition

    A Antinori;T Coenen;D Costagiola;N Dedes

  • The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals

    Maile Ray;Roger Logan;Jonathan A C Sterne;Sonia Hernández-Díaz

  • Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals

    Ard I. van Sighem;Luuk A. J. Gras;Peter Reiss;Kees Brinkman

  • Variation in HIV-1 set-point viral load: Epidemiological analysis and an evolutionary hypothesis

    Christophe Fraser;T. Déirdre Hollingsworth;Ruth Chapman;Frank de Wolf

  • Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.

    J. M. A. Lange;D. A. Paul;H. G. Huisman;F. De Wolf

  • Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study

    Linda Wittkop;Huldrych F Günthard;Frank de Wolf;David Dunn

  • Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture.

    H. Schuitemaker;N. A. Kootstra;R. E. Y. De Goede;F. De Wolf

  • T cell telomere length in HIV-1 infection: No evidence for increased CD4(+) T cell turnover

    Katja C. Wolthers;G. Bea;A. Wisman;Sigrid A. Otto

  • Association between CCR5 Genotype and the Clinical Course of HIV-1 Infection

    A.M. de Roda Husman;M. Koot;M.T.E. Cornelissen;I.P.M. Keet

  • Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.

    G Chêne;J A C Sterne;M May;D Costagliola

  • When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study

    Lauren E Cain;Roger Logan;James M Robins;Jonathan A C Sterne

  • HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.

    May Mt;Sterne Ja;Costagliola D;Sabin Ca

  • Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy

    J.M. Prins;S. Jurriaans;van R.M.E. Praag;H. Blaak

  • Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries.

    Zwahlen M;Harris R;May M

  • Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine

    D W Notermans;S Jurriaans;F de Wolf;N A Foudraine

  • Mortality and progression to AIDS after starting highly active antiretroviral therapy.

    van Ai Sighem;van de Ma Mark Wiel;AC Ghani;M Jambroes

  • Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS

    C.A. van Baalen;O. Pontesilli;R.C. Huisman;A.M. Geretti

  • Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam.

    J. A. R. van den Hoek;H. J. A. van Haastrecht;J. Goudsmit;F. de Wolf

  • CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater.

    Luuk Gras;Anouk M Kesselring;James T Griffin;Ard I van Sighem

Frequent Co-Authors

Jaap Goudsmit
Jaap Goudsmit Harvard University
R. A. Coutinho
R. A. Coutinho University of Amsterdam
Frank Miedema
Frank Miedema Utrecht University
Marijke T. L. Roos
Marijke T. L. Roos University of Amsterdam
Geneviève Chêne
Geneviève Chêne University of Bordeaux
Robert S. Hogg
Robert S. Hogg Simon Fraser University
Margaret T May
Margaret T May University of Bristol
Jonathan A C Sterne
Jonathan A C Sterne University of Bristol
Suzanne Jurriaans
Suzanne Jurriaans University of Amsterdam

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in Immunology offers diverse opportunities, with many professionals opting for related healthcare fields like nursing to complement their expertise. For those considering advanced nursing roles, exploring easy nurse practitioner programs to get into can provide accessible entry points without compromising quality education.

Specializing further, Psychiatric Mental Health Nurse Practitioner (PMHNP) programs are highly sought after for their focus on mental health—a critical area that intersects with immunological research and patient care. Students often prioritize reputable options, making the top online pmhnp programs an essential consideration for both quality training and practical clinical experience.

Cost is a significant factor when choosing educational paths. For budget-conscious students, discovering the cheapest online pmhnp programs can help balance financial constraints with career advancement goals.

Understanding the financial returns of advanced nursing roles is also vital. Those interested in doctorate-level education can explore insights on dnp salary by state to assess potential earnings and geographic opportunities in healthcare.

Best Scientists Citing F. de Wolf

Trending Scientists

Recently Published Articles